|Bid||0.00 x 1800|
|Ask||57.94 x 1200|
|Day's range||57.37 - 58.10|
|52-week range||56.66 - 69.75|
|Beta (5Y monthly)||0.63|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||1.96 (3.39%)|
|Ex-dividend date||30 Sep 2021|
|1y target est||N/A|
Bristol Myers Squibb (BMY) closed the most recent trading day at $57.81, moving -0.45% from the previous trading session.
(Bloomberg) -- Bristol-Myers Squibb Co. is planning to tender its shares in Acceleron Pharma Inc. after Merck & Co. agreed to buy the biotechnology company for $11.5 billion, according to people with knowledge of the matter. Most Read from BloombergGoogle’s Biggest Moonshot Is Its Search for a Carbon-Free FutureA $30 Billion Fortune Is Hiding in China’s Silicon ValleyBeef Industry Tries to Erase Its Emissions With Fuzzy Methane MathGoogle’s CEO: ‘We’re Losing Time’ in the Climate FightHate-Speec
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.